National Cancer Institute

February 16, 2021February 16, 2021

InVivo Analytics Granted $1.7M to Advance Preclinical 3D Imaging

News

InVivo Analytics has received $1.7 million to develop and commercialize its next-generation fluorescence imaging device, called InVivoFLUOR, for 3D monitoring of immune cell migration in animal models of cancer, the ... Read more

November 19, 2020November 19, 2020

Study to Examine if Blood Test Can Detect Cancer Early in Low-Risk Women

News

The University of Texas’ MD Anderson Cancer Center, in collaboration with the National Cancer Institute and Golfers Against Cancer, is evaluating the usefulness of a blood test called CA-125 at detecting ovarian cancer ... Read more

October 15, 2020October 15, 2020

First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC

News

The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the immune ... Read more

February 24, 2020February 24, 2020

University of Sydney Given $3.75M Grant to Study Personalized Ovarian Cancer Treatments

News

The Australian Cancer Council NSW has awarded its annual $3.75 million Translational Program Grant to a University of Sydney research team to explore better ways to personalize ovarian cancer treatments. ... Read more

September 13, 2019

TCR2 Therapeutics, National Cancer Institute Team Up to Develop TC-210 Immunotherapy

News

TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, in an ongoing Phase 1/2 clinical trial for people with advanced ... Read more

September 24, 2018

Adding Yervoy to Opdivo Increases Responses in Some Ovarian Cancer Patients, Phase 2 Study Shows

News

A combination of Opdivo (nivolumab) and Yervoy (ipilimumab) leads to better response rates in patients with persistent or recurrent ovarian cancer than Opdivo alone, a Phase 2 study shows. The ... Read more

June 25, 2018

Splash Begins Expansion Phase of SPL-108 Trial for Ovarian Cancer Patients

News

Splash Pharmaceuticals has successfully completed the safety stage of its Phase 1 trial testing a combination of SPL-108 and chemotherapy in platinum-resistant ovarian cancer patients, the company announced in a press release. Taking ... Read more